Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

Jennifer shows CRS timing differs by drug: glofitamab peaks at the first 2.5 mg step-up, epcoritamab at its first full dose, and mosunetuzumab at the third dose. Follicular lymphoma's extra epcoritamab step-up lowered high-grade CRS. Outpatient monitoring must match the exact agent and dose in practice.

Related Insights

The full FDA approval of the T-cell engager tarlatumab introduces significant logistical hurdles. Due to the high risk of Cytokine Release Syndrome (CRS), which occurred in over 50% of patients, the label requires 22-hour on-site monitoring after the first two doses. This presents practical challenges for outpatient infusion centers and requires new patient support infrastructure.

When choosing a bispecific antibody for follicular lymphoma, a major practical difference is the treatment duration. Mosunetuzumab is a time-limited therapy stopped after achieving a complete response, while Epcoritamab is given indefinitely until progression. This distinction heavily influences selection, especially for elderly patients.

The acute toxicity risk during the initial ramp-up phase of bispecific antibodies (like CRS and ICANS) makes them challenging to manage in a typical community oncology setting. A safer model involves academic centers managing the high-risk initiation period before transitioning the patient back to their community provider for ongoing care.

A modified three-step-up dosing schedule for epcoritamab drastically reduced cytokine release syndrome (CRS) rates to 26%, with no severe events. This safety profile supports fully outpatient administration, making this highly effective regimen accessible to community practices without immediate hospital access.

Manali explains glofitamab binds the same CD20 epitope as obinutuzumab and had high CRS, so the label requires obinutuzumab seven days before the first step-up. Mosunetuzumab shares rituximab's epitope, meaning a mosunetuzumab-rituximab combination would compete for the same binding domain. That mechanistic detail shapes regimen design.

Contrary to fears based on T-cell engagers in hematologic cancers, CRS with the DLL3 bispecific tarlatamab in SCLC is typically mild and easily managed. An expert describes it as "scary until you're treating patients and then you find that it's pretty anticlimactic," reassuring community oncologists about the therapy's safety profile.

Using the bispecific antibody epcoritamab directly in CLL patients with active disease triggers severe cytokine release syndrome due to high circulating disease burden. Administering fixed-duration venetoclax beforehand debulks tumor load, resulting in significantly lower cytokine release syndrome rates while achieving high undetectable minimal residual disease responses.

Jennifer cites a retrospective glofitamab analysis where dexamethasone was associated with lower CRS or less need for additional support than other steroids. Its longer half-life and greater potency made dexamethasone the preferred steroid at Dana-Farber, although she notes the evidence is only retrospective for this drug class.

In clinical practice for relapsed large cell lymphoma, glofitumab is a preferred bispecific antibody. Clinicians favor it over epcoritamab because it is time-limited (vs. indefinite treatment) and has a more patient-friendly every-three-week schedule, while also being more active than mosunetuzumab.

Giving prophylactic tocilizumab before bispecific antibody administration is a highly effective strategy to mitigate Cytokine Release Syndrome (CRS). This approach can reduce CRS rates from ~70% to 5-14%, making outpatient step-up dosing a much more feasible and safer option for community oncology centers.